These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24003936)

  • 1. Glucagon-like peptide-1: modulator of β-cell dysfunction and death.
    Rondas D; D'Hertog W; Overbergh L; Mathieu C
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():185-92. PubMed ID: 24003936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based therapy and type 2 diabetes.
    Hare KJ; Knop FK
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G; Thomaseth K; Ahrén B
    Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.
    De León DD; Crutchlow MF; Ham JY; Stoffers DA
    Int J Biochem Cell Biol; 2006; 38(5-6):845-59. PubMed ID: 16202636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA; Vahl TP
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 based therapy for type 2 diabetes.
    Arulmozhi DK; Portha B
    Eur J Pharm Sci; 2006 May; 28(1-2):96-108. PubMed ID: 16488579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of incretin on diabetes mellitus.
    Sanusi H
    Acta Med Indones; 2009 Oct; 41(4):205-12. PubMed ID: 20737753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic].
    Göke B; Fehmann HC; Schirra J; Hareter A; Göke R
    Z Gastroenterol; 1997 Apr; 35(4):285-94. PubMed ID: 9221612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses.
    Rijkelijkhuizen JM; McQuarrie K; Girman CJ; Stein PP; Mari A; Holst JJ; Nijpels G; Dekker JM
    Metabolism; 2010 Apr; 59(4):502-11. PubMed ID: 19846181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.
    Riedel MJ; Gaddy DF; Asadi A; Robbins PD; Kieffer TJ
    Gene Ther; 2010 Feb; 17(2):171-80. PubMed ID: 19865180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.